FDA gives accelerated approval to Genmab and Seagen's cervical cancer drug

Genmab and Seagen have received accelerated approval from the FDA for tisotumab vedotin, used to treat recurring or metastatic cervical cancer.

Photo: Joost Melis / Genmab / PR

Genmab and its partner Seagen have obtained accelerated approval for tisotumab vedotin, commercial name Tivdak, for the treatment of recurring or metastatic cervical cancer, from the US Food and Drug Administration (FDA).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs